Metastatic Colorectal Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

Metastatic Colorectal Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

October 10
22:08 2023
Metastatic Colorectal Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in the Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

  • DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 130+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.
  • The leading companies working in the Metastatic Colorectal Cancer Market include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
  • Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.
  • September 2023: Bristol-Myers Squibb announced a study of phase 3 clinical trials for Ipilimumab, Oxaliplatin, and Leucovorin. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
  • October 2023: Arcus Biosciences Inc. announced a study of Phase 1 & 2 clinical trials for AB680, Etrumadenant, Zimberelimab, and Bevacizumab. This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

 

Request a sample and discover the recent advances in Metastatic Colorectal Cancer Treatment Drugs @ Metastatic Colorectal Cancer Pipeline Report

 

In the Metastatic Colorectal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Metastatic Colorectal Cancer Overview

Cancer cells may break away from a tumor in the colon or rectum and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ. Even though the cancer has spread to a new organ, it is still named after the part of the body where it originally started.

 

Find out more about Metastatic Colorectal Cancer Therapeutics Assessment @ Metastatic Colorectal Cancer Preclinical and Discovery Stage Products

 

Metastatic Colorectal Cancer Emerging Drugs Profile

  • Adagrasib (MRTX849): Mirati Therapeutics
  • QL-1203: Qilu Pharmaceutical
  • ZN-c3: Zentalis Pharmaceuticals

 

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the Metastatic Colorectal Cancer pipeline therapies. The Metastatic Colorectal Cancer companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

 

Learn more about the emerging Metastatic Colorectal Cancer Pipeline Therapies @ Metastatic Colorectal Cancer Clinical Trials Assessment

 

Scope of the Metastatic Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
  • Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.

 

Dive deep into rich insights for new drugs for Metastatic Colorectal Cancer Treatment, Visit @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic colorectal cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Metastatic colorectal cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. MRTX849: Mirati Therapeutics
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. AK-112: Akeso Biopharma
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. SY 5609: Syros Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Metastatic colorectal cancer Key Companies
  23. Metastatic colorectal cancer Key Products
  24. Metastatic colorectal cancer- Unmet Needs
  25. Metastatic colorectal cancer- Market Drivers and Barriers
  26. Metastatic colorectal cancer- Future Perspectives and Conclusion
  27. Metastatic colorectal cancer Analyst Views
  28. Metastatic colorectal cancer Key Companies
  29. Appendix

 

For further information on the Metastatic Colorectal Cancer Pipeline therapeutics, reach out to Metastatic Colorectal Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Related Articles

Categories